Semaglutide Steps In: New Hope for PAD Patients

This episode explores new randomized evidence that semaglutide, a GLP-1 receptor agonist used for diabetes and weight loss, can improve walking distance and quality of life for people with type 2 diabetes and symptomatic peripheral arterial disease (PAD). The landmark STRID trial showed median gains of about 26 meters (mean ~40 m) in walking distance over a year, along with better pain scores and daily function. Large real-world studies also suggest fewer PAD-related hospitalizations and amputations. Benefits likely come from multiple effects: weight loss and improved glucose control, anti-inflammatory actions, better endothelial function and muscle metabolism, all combining to improve perfusion and exercise capacity. Semaglutide is an adjunct to standard PAD care (exercise, smoking cessation, statins, antiplatelets, revascularization when needed). Common side effects include GI symptoms; monitor eye health, pancreatitis risk, and avoid use in patients with MEN2 or medullary thyroid cancer history.